
DXCM
USDDexCom Inc. Common Stock
السعر في الوقت الحقيقي
مخطط الأسعار
المقاييس الرئيسية
مقاييس السوق
الافتتاح
$61.090
الأعلى
$62.390
الأدنى
$58.880
الحجم
8.96M
أساسيات الشركة
القيمة السوقية
23.9B
الصناعة
الأجهزة الطبية
البلد
United States
إحصاءات التداول
متوسط الحجم
5.54M
البورصة
NMS
العملة
USD
نطاق 52 أسبوعاً
تقرير تحليل الذكاء الاصطناعي
آخر تحديث: ٤ نوفمبر ٢٠٢٥DXCM Analysis: DexCom's Rocky Road - Can Recent Bounce Hold?
Market Pulse Check
- Current Price: $60.43 (as of 2025-11-03 close)
- Recent Swing: +3.8% rebound after 61% decline since August highs
- Key Technicals: MACD bearish crossover vs. surging 19x average volume
Price Action Breakdown
- August-Sept Stability: Traded $75-$82 range
- Sept 19 Crash: -11% drop on 3x average volume
- October Freefall: 35% decline accelerated by legal news
- November Lifeline: +3.8% gain on massive 17.8M shares traded
News Impact Matrix
| Sentiment | Count | Key Developments |
|---|---|---|
| Negative | 9 | 6 law firm investigations filed |
| Analyst Mixed | 12 | 8 lowered PTs (range $75-$99) |
| Positive | 1 | New board member appointment |
AI Forecast Snapshot
| Timeframe | Prediction | Notes |
|---|---|---|
| 1-day | -0.8% | Potential pullback after surge |
| 2-day | +1.6% | Technical rebound potential |
| 3-day | +1.9% | Resistance near $62 area |
Strategic Considerations
For Active Traders:
- Watch $61.15 breakout level (Nov 3 high)
- Consider partial profits at $62.90 TP
- Hard stop below $58.50 support
Long-term Investors:
- Monitor lawsuit developments closely
- Debt concerns (94% D/E ratio) require scrutiny
- Potential accumulation zone if $58 holds
Bottom Line
DexCom's technical bounce faces fundamental headwinds. While AI models suggest near-term upside, the legal overhang creates exceptional risk. The stock needs to reclaim $62 decisively to suggest sustainable recovery. Healthcare sector exposure remains favorable, but DXCM requires tighter risk parameters than peers.
This analysis reflects market conditions as of November 4, 2025. Consider consulting a financial advisor before making investment decisions. Past performance doesn't guarantee future results. Data sources: Analyst reports, SEC filings, market data feeds.
أخبار ذات صلة
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. (NASDAQ:...
UBS Maintains Buy on DexCom, Lowers Price Target to $95
UBS analyst Danielle Antalffy maintains DexCom with a Buy and lowers the price target from $106 to $95.
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82
Truist Securities analyst Richard Newitter reiterates DexCom with a Buy and lowers the price target from $94 to $82.
Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80
Barclays analyst Matt Miksic maintains DexCom with a Equal-Weight and lowers the price target from $98 to $80.
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or...
DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM) - Contact Kessler Topaz Meltzer & Check, LLP
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against...
Wells Fargo Maintains Overweight on DexCom, Lowers Price Target to $93
Wells Fargo analyst Larry Biegelsen maintains DexCom with a Overweight and lowers the price target from $98 to $93.
تنبؤ الذكاء الاصطناعيBeta
توصية الذكاء الاصطناعي
تم التحديث في: ٤ نوفمبر ٢٠٢٥، ٠٩:٠٩ م
60.6% الثقة
المخاطر والتداول
نقطة الدخول
$58.80
جني الأرباح
$62.91
وقف الخسارة
$52.39
العوامل الرئيسية
أسهم ذات صلة
ابق على اطلاع
تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.